About: Case reports study of the first five patients COVID-19 treated with remdesivir in France

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Case reports study of the first five patients COVID-19 treated with remdesivir in France Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Case reports study of the first five patients COVID-19 treated with remdesivir in France
Creator	Houhou-Fidouh, Nadhira Visseaux, Benoit Yazdanpanah, Yazdan Dubert, Marie Bouadma, Lila Lescure, Francois-Xavier Kramer, Laura Le Hingrat, Quentin Wicky, Paul-Henri Ghosn, Jade Patrier, Juliette Rioux, Christophe Deconinck, Laurène Le Pluart, Diane Affiliations, $ Isernia, Valentina
Source	Elsevier; Medline; PMC
abstract	Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as responsible for the COVID-19 outbreak worldwide. Data on treatment are scare and parallels are made between SARS-CoV-2 and other coronavirus. Remdesivir is a broad spectrum antiviral with efficient in vitro activity against SARS-CoV-2 and controversial evidence of clinical improvement in severe COVID-19 patients. We aimed to describe the clinical outcome and virological monitoring of the first five COVID-19 patients admitted in ICU for severe pneumonia related to SARS-CoV-2 and treated with remdesivir in the University hospital of Bichat, Paris, France. SARS-CoV-2 RT-qPCR in blood plasma, lower and upper respiratory tract were monitored. Among the five treated patients, two needed mechanical ventilation and one high flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load from upper respiratory tract was observed in most cases but two died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted for side effects among four patients, including 2 ALT elevations (3 to 5 N) and 2 renal failures requiring renal replacement. This case series of five COVID-19 patients requiring ICU for a respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.06.093
bibo:pmid	32619764
has license	els-covid
sha1sum (hex)	d86608f2aa0fea87b00d76d7ed9dfaa24fba18de
schema:url	https://doi.org/10.1016/j.ijid.2020.06.093
resource representing a document's title	Case reports study of the first five patients COVID-19 treated with remdesivir in France
has PubMed Central identifier	PMC7326458
has PubMed identifier	32619764
schema:publication	Int J Infect Dis
resource representing a document's body	covid:d86608f2aa0fea87b00d76d7ed9dfaa24fba18de#body_text
is schema:about of	named entity 'INHIBITOR' named entity 'DID' named entity 'AGENCIES' covid:arg/d86608f2aa0fea87b00d76d7ed9dfaa24fba18de named entity 'in-vivo' named entity 'Remdesivir' named entity 'RNA viruses' named entity 'not-for-profit' named entity 'COVID-19' named entity 'chest CT scan' named entity 'nasopharyngeal' named entity 'acute respiratory failure' named entity 'multiorgan failure' named entity 'dashed' named entity 'RT-qPCR' named entity 'Aspergillus flavus' named entity 'China' named entity 'case reports' named entity 'France' named entity 'remdesivir' named entity 'retrospective chart review' named entity 'lymphopenia' named entity 'Betacoronavirus' named entity 'mass spectrometry' named entity 'viral load' named entity 'kidney failure' named entity 'RNA' named entity 'multiplex PCR' named entity 'COVID' named entity 'detection limit' named entity 'Grein' named entity 'COVID-19' named entity 'respiratory symptoms' named entity 'kidney injury' named entity 'follow-up' named entity 'nasopharyngeal' named entity 'January 29' named entity 'G/L' named entity 'case reports' named entity 'remdesivir' named entity 'viral load' named entity 'thyroid cancer' named entity 'immunomodulatory drugs' named entity 'Multiple organ failures' named entity 'prodrug' named entity 'COVID' named entity 'Gilead Sciences' named entity 'SARS-CoV-2' named entity 'broad spectrum' named entity 'multiple organ failures' named entity 'oxygen saturation' named entity 'randomized study' named entity 'alveolar' named entity 'lung' named entity 'Virus' named entity 'coinfection' named entity 'BioMérieux' named entity 'oxygen' named entity 'February 21' named entity 'blue line' named entity 'tracheal' named entity 'remdesivir' named entity 'lower respiratory tract' named entity 'in-vitro' named entity 'infection' named entity 'Paris'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software